Verified
The first month brought night sweats and restless sleep. My oncology nurse suggested tracking the timing rather than stopping the tablets, and the symptoms became easier to manage.
14 Oct 2026
Nolvadex
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Nolvadex is a prescription medicine containing tamoxifen citrate for adults with hormone-receptor-positive breast cancer or selected high breast cancer risk. It helps reduce oestrogen-driven stimulation in breast tissue by changing how oestrogen receptors respond.
Description
Nolvadex is a prescription tablet containing tamoxifen citrate, a selective oestrogen receptor modulator. It is used mainly for hormone-receptor-positive breast cancer in adults and for risk reduction in selected high-risk patients. Tamoxifen blocks oestrogen stimulation in breast tissue while producing different receptor effects in bone and other tissues.
Composition
Nolvadex contains tamoxifen citrate, which provides tamoxifen as the pharmacologically active component. The product is supplied as tablets, with 30 tablets in the pack. Tamoxifen belongs to the non-steroidal selective oestrogen receptor modulator group, often abbreviated as SERM.
Nolvadex is a prescription-only medicine. Its use must be directed by a licensed healthcare professional because treatment length, monitoring, and risk factors vary between patients.
Active ingredient profile
Tamoxifen is a synthetic, non-steroidal molecule that binds to oestrogen receptors. The effect depends on the tissue. In breast tissue, it mainly blocks oestrogen-driven signalling. In bone and some other tissues, it can produce partial oestrogen-like activity.
| Product strength | Active ingredient | Drug class |
|---|---|---|
| Tablet | Tamoxifen citrate | Selective oestrogen receptor modulator |
The dose is stated on the pack — follow the leaflet. Tablet strength should never be altered by splitting or combining tablets unless the prescriber has given specific instructions.
Tamoxifen is commonly taken at the same time each day. A fixed routine, such as taking it after breakfast, can reduce missed doses without changing the drug’s effect.
A useful practical detail is that tamoxifen is converted in the liver into active metabolites, including endoxifen. The CYP2D6 enzyme contributes to this conversion, so some medicines that inhibit CYP2D6 can reduce exposure to active metabolites [1].
Dosage and usage
The dose is stated on the pack — follow the leaflet. The prescriber may select a different schedule in unusual clinical circumstances, but patients should not change the dose independently.
- Take the prescribed tablet by mouth with water.
- Take it at approximately the same time each day.
- It may be taken with food or on an empty stomach.
- Swallow the tablet whole unless a prescriber gives a specific alternative instruction.
- Continue treatment for the duration set by the oncology team.
- If a dose is missed, take it when remembered unless the next dose is close; do not double the next dose.
Tamoxifen treatment can continue for several years in adjuvant breast cancer care. The precise duration depends on recurrence risk, menopausal status, tolerance, and prior endocrine treatment.
The schedules described in some fertility-treatment protocols are not a routine substitute for the oncology dose and should not be copied for self-treatment. Fertility use requires a separate diagnosis, ovulation assessment, and specialist prescribing.
Do not compensate for a missed tablet by taking two tablets together. A double dose can increase adverse effects without restoring the intended treatment schedule.
Tamoxifen can be taken in the morning or evening. Evening dosing may suit someone who experiences nausea, while morning dosing may be easier for a patient who already uses daily medicines after breakfast.
How it works
Tamoxifen enters cells and binds to oestrogen receptors. The drug changes the shape of the receptor and influences whether oestrogen-responsive genes are activated. In hormone-receptor-positive breast cancer, this reduces the growth stimulus supplied by oestrogen.
The action is tissue-selective rather than uniformly anti-oestrogenic. This explains why tamoxifen can protect breast tissue from oestrogen stimulation while retaining partial oestrogen-like effects in bone.
Receptor antagonism in breast tissue
In breast cancer cells with oestrogen receptors, tamoxifen competes with oestradiol for receptor binding. The tamoxifen-receptor complex recruits different regulatory proteins from those recruited by natural oestrogen. Cellular proliferation may therefore slow, which supports adjuvant treatment after surgery and treatment of advanced disease.
Tamoxifen does not remove oestrogen from the bloodstream. It changes how certain tissues respond to it.
Tamoxifen compared with an aromatase inhibitor
Aromatase inhibitors, such as anastrozole, reduce the formation of oestrogen from androgen precursors. Tamoxifen works at the receptor level. The two approaches may be selected according to menopausal status, recurrence risk, previous treatment, bone health, and the wider oncology plan.
| Treatment approach | Main action | Common clinical consideration |
|---|---|---|
| Tamoxifen | Blocks oestrogen signalling in breast tissue | Used in premenopausal and postmenopausal patients |
| Aromatase inhibition | Reduces peripheral oestrogen production | Often used after menopause, with bone health assessment |
The National Cancer Institute and European Medicines Agency describe tamoxifen as an endocrine treatment for oestrogen-receptor-positive breast cancer. It does not replace chemotherapy, radiotherapy, surgery, or targeted treatment when those treatments are indicated.
Indications
Nolvadex is mainly prescribed for hormone-receptor-positive breast cancer. It may be used after primary treatment to lower the chance of recurrence, or for advanced disease when cancer has spread or returned.
Common clinical settings include:
- Adjuvant treatment after surgery for hormone-sensitive breast cancer.
- Treatment of metastatic breast cancer.
- Treatment of recurrent disease when tumour cells retain hormone receptors.
- Risk reduction in selected people with a substantially increased risk of breast cancer.
- Endocrine treatment before or after other oncology therapies, depending on the treatment plan.
The benefit depends on tumour biology. Tamoxifen is less useful when the cancer lacks oestrogen receptors, so pathology results guide treatment selection. Receptor testing is usually performed on tumour tissue. The oncology team combines the result with stage, menopausal status, and previous treatment. A treatment plan may change if the disease biology changes.
Comparison
Tamoxifen compared with an aromatase inhibitor
Aromatase inhibitors, such as anastrozole, reduce the formation of oestrogen from androgen precursors. Tamoxifen works at the receptor level. The two approaches may be selected according to menopausal status, recurrence risk, previous treatment, bone health, and the wider oncology plan.
| Treatment approach | Main action | Common clinical consideration |
|---|---|---|
| Tamoxifen | Blocks oestrogen signalling in breast tissue | Used in premenopausal and postmenopausal patients |
| Aromatase inhibition | Reduces peripheral oestrogen production | Often used after menopause, with bone health assessment |
The National Cancer Institute and European Medicines Agency describe tamoxifen as an endocrine treatment for oestrogen-receptor-positive breast cancer. It does not replace chemotherapy, radiotherapy, surgery, or targeted treatment when those treatments are indicated.
Contraindications
Tamoxifen should not be used during pregnancy. It can harm fetal development, and pregnancy should be excluded before treatment where clinically relevant. Effective non-hormonal contraception is recommended during treatment and for the period specified by the prescriber after the final dose.
Tamoxifen can inhibit lactation and should not be used to suppress milk production without a specific medical indication. Breastfeeding is generally avoided during treatment because drug exposure through milk and effects on the infant have not been established as acceptable.
Drug interactions
Strong CYP2D6 inhibitors can reduce formation of endoxifen. Paroxetine, fluoxetine, and some other antidepressants may therefore reduce tamoxifen activation. The prescriber should review antidepressants before treatment begins.
Tamoxifen may increase the anticoagulant effect of warfarin and related medicines. Clotting tests may need closer monitoring. Hormonal contraceptives and hormone replacement therapy also require review because they can conflict with the treatment goal in hormone-sensitive breast cancer.
Tell the oncology team about all medicines, including antidepressants, anticoagulants, herbal products, and non-prescription pain medicines. Grapefruit is not the main interaction concern with tamoxifen; CYP2D6 inhibition and anticoagulant effects deserve more attention.
When this is not for you
This medication is not for you if
- You have a known allergy to tamoxifen or any tablet ingredient.
- You are pregnant or trying to become pregnant.
- You are taking tamoxifen to reduce breast cancer risk while also receiving coumarin-type anticoagulant treatment.
- You have a history of deep-vein thrombosis or pulmonary embolism and the prescriber has judged the risk unacceptable.
- You have unexplained vaginal bleeding that has not been assessed.
- You are taking medicines that make tamoxifen unsuitable for your medical condition.
Side effects
Tamoxifen is widely used, but its benefits must be balanced against clinically important risks. The most frequent problems include hot flushes, sweating, nausea, tiredness, mood changes, vaginal discharge, and menstrual irregularity.
Some effects improve after the first weeks. Others persist and require a treatment review.
Common effects
Patients may experience:
- Hot flushes and night sweats.
- Nausea or stomach discomfort.
- Headache or dizziness.
- Tiredness.
- Fluid retention.
- Vaginal discharge, dryness, or irritation.
- Irregular periods in premenopausal patients.
- Reduced libido or mood changes.
- Muscle or joint discomfort.
Nausea may be easier to manage when the tablet is taken with food. Persistent vomiting, severe fatigue, or symptoms that interfere with daily activity require a medication review rather than silent discontinuation.
Serious adverse effects
Seek urgent medical assessment for:
- Sudden chest pain, breathlessness, coughing blood, or one-sided leg swelling.
- New weakness, facial drooping, speech difficulty, or sudden visual disturbance.
- Unusual vaginal bleeding, pelvic pain, or a change in vaginal discharge after menopause.
- Severe abdominal pain or yellowing of the skin.
- A sudden severe headache or loss of coordination.
Tamoxifen is associated with venous thromboembolism, including deep-vein thrombosis and pulmonary embolism. It is also associated with changes in the endometrium, including a small increased risk of endometrial cancer after prolonged exposure. Unusual vaginal bleeding needs prompt investigation.
A hot flush is uncomfortable but usually not an emergency. One-sided calf swelling, sudden breathlessness, or chest pain is different and needs urgent assessment.
Tamoxifen can affect visual function. Blurred vision, difficulty distinguishing colours, or persistent visual changes should be reported promptly because retinal and lens changes have been described during treatment.
Common mistakes
Several mistakes can reduce treatment reliability or delay recognition of complications.
- Stopping tamoxifen abruptly because hot flushes become uncomfortable.
- Taking two tablets after a missed dose.
- Starting an antidepressant without checking for CYP2D6 inhibition.
- Assuming that herbal products cannot affect cancer treatment.
- Ignoring vaginal bleeding after menopause.
- Treating new calf swelling as a minor muscle strain.
- Sharing tablets with a family member who has similar symptoms.
- Using tamoxifen for post-cycle therapy or bodybuilding-related hormone management without oncology or endocrine supervision.
- Crushing or splitting a tablet without a specific instruction.
- Forgetting to tell a surgeon or dentist about ongoing endocrine treatment.
One practical distinction matters: tamoxifen is not an aromatase inhibitor and does not provide instant reduction of aromatase activity. It also does not reliably prevent all oestrogen-related symptoms outside its approved clinical role.
People sometimes expect the medicine to restore fertility or raise testosterone. Those outcomes are not the purpose of adjuvant breast cancer treatment and should not guide self-directed dosing.
What doctors say
In clinical practice, oncologists usually frame tamoxifen as long-term risk reduction rather than a medicine that produces an immediate sensation. Its value comes from sustained receptor blockade over months and years.
A common prescribing error is to judge treatment by hot flushes or the absence of symptoms. Side effects do not reliably show whether tamoxifen is controlling hormone-sensitive cancer. Conversely, feeling well does not mean the medicine has stopped working.
Doctors also review the reason for each concurrent medicine. An antidepressant selected for hot flushes may be unsuitable if it strongly inhibits CYP2D6. A medication change can sometimes preserve symptom relief while reducing a pharmacokinetic interaction.
Bone health receives attention because tamoxifen has tissue-selective effects. Its influence differs before and after menopause, so fracture risk, vitamin D status, physical activity, and other endocrine treatments may affect the wider plan.
Keep a written list of every medicine and supplement used during oncology treatment. The most useful detail is the active ingredient, not only the product name.
A prescriber may recommend blood tests, gynaecological assessment, eye review, or clot-risk assessment according to symptoms and personal history. These checks are targeted rather than identical for every patient.
Frequently asked questions
How long does Nolvadex take to work?
Tamoxifen begins binding to oestrogen receptors after treatment starts, but the clinical benefit is assessed over a longer period rather than by daily sensations. The National Cancer Institute's 2024 breast cancer information describes endocrine treatment as a sustained strategy in hormone-receptor-positive breast cancer. Treatment response is evaluated through the cancer plan, examinations, imaging, and pathology rather than by symptom changes alone.
Can Nolvadex be used during pregnancy?
No. Tamoxifen should not be used during pregnancy because fetal harm is possible. The World Health Organization's 2024 safety information treats pregnancy avoidance as a key principle for endocrine medicines with reproductive effects, and contraception planning should be addressed before treatment begins.
Does Nolvadex cause infertility?
Tamoxifen can alter menstrual patterns and fertility-related hormone signalling, but the effect differs between patients. The European Medicines Agency's 2018 product information describes reproductive precautions because pregnancy can occur during treatment despite irregular cycles. Fertility planning should be discussed before treatment, since tamoxifen is not used as a general fertility supplement.
Can Nolvadex be taken with antidepressants?
Some antidepressants interact with tamoxifen by inhibiting CYP2D6, the enzyme involved in forming the active metabolite endoxifen. The FDA highlighted this interaction in its 2018 tamoxifen prescribing information, with paroxetine and fluoxetine receiving particular attention. A prescriber should select or adjust antidepressant treatment according to psychiatric needs and the oncology plan.
Does Nolvadex increase the risk of blood clots?
Tamoxifen is associated with an increased risk of venous thromboembolism, including deep-vein thrombosis and pulmonary embolism. NICE breast cancer guidance from 2018 identifies clot symptoms as a reason for urgent clinical assessment, especially in people with previous clotting events or additional risk factors. Sudden breathlessness, chest pain, or one-sided leg swelling should not be monitored at home.
What should happen if unusual vaginal bleeding occurs?
Unexpected vaginal bleeding, especially after menopause, requires prompt medical assessment during tamoxifen treatment. The American College of Obstetricians and Gynecologists described in 2014 the need to investigate postmenopausal bleeding because tamoxifen can affect the endometrium. The symptom does not prove cancer, but delaying assessment is unsafe.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Nolvadex: Reviews and Experiences
3.4
Based on 4 reviews
Verified
I had very few symptoms, which made the daily tablet easy to forget. A phone reminder after breakfast helped me keep the routine consistent.
15 Sept 2026
Verified
My mood changed after starting treatment, and I initially blamed work stress. The review found that another medicine was affecting the tamoxifen plan, so my prescriptions were adjusted. I am still unhappy with how difficult the treatment has been.
26 Sept 2026
Verified
Unexpected bleeding was the symptom I nearly ignored. Investigation found a uterine problem that needed treatment, so I was relieved I reported it early.
06 Oct 2026
Sources
- U.S. Food and Drug Administration (2018). Nolvadex (tamoxifen citrate) prescribing information.
